Background: Urinary tract infections (UTIs) are common. Antibiotic treatment is usually empirical, with the risk of under-treatment of resistant infections.
Introduction
Antimicrobial resistance (AMR) is an increasing global health threat. 1 Resistance among invasive Gram-negative bacterial isolates in Europe and the USA is high and increasing, 2, 3 including MDR. MDR is associated with increased treatment failures and costs, and increased morbidity and mortality. 4, 5 In Scotland, resistance among Gram-negative bacteraemia remains high, particularly to antibiotics commonly prescribed for urinary tract infection (UTI). 6 In 2015, Escherichia coli bacteraemia in Scotland had an incidence of 85.5 per 100000 population, 4.9% higher than in 2012. 6 A key action of the UK Five Year Antimicrobial Resistance Strategy 2013-2018 is better access to and use of surveillance data and improved data linkage. 7 NHS Scotland has developed an Infection Intelligence Platform (IIP), which has increased informatics capability and capacity to link routinely collected national data, with a particular aim of enabling patient-centred treatment through modelling patient-specific risk factors. 8 UTI is the second most common reason for use of antibiotics in the community. 9 Initial antibiotic treatment is usually empirical, where the prescriber has no information on the causative organism or antibiotic susceptibility. In Scotland national guidance recommends nitrofurantoin or trimethoprim as first-line empirical treatment of uncomplicated UTI. 10 However, these empirical options may not be appropriate for patients with high risk of antibiotic resistance. The aim of this study was to quantify risk factors for AMR in urine isolates using individual-level routine national data linked within the IIP.
Methods
NHS National Services Scotland (NSS) hosts national health and demographic data on behalf of NHS Scotland. In Scotland, all individuals have a unique patient identifier, the Community Health Index (CHI) number, which enables records for the same patient to be linked across multiple datasets. 11 Within the IIP, the CHI is used to link specific data; patient identifiers are then removed for anonymized analysis.
Data sources
The Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland (SARUIS) dataset records culture and susceptibility data for a large, representative subset of all positive urine isolates in Scotland. 12 All NHS Boards are required to submit data on the first 400 consecutive positive urine samples per calendar quarter. Demographic data were obtained from SARUIS.
Patient-level data on hospitalizations were obtained from the NSS General/Acute Inpatient and Day Case dataset (SMR01), 13 and on all dispensed community NHS prescriptions in the previous 12 months from the NSS Prescribing Information System (PIS). 13 
Cohort identification and variable classification
The study cohort was identified from records with a valid CHI number in the SARUIS dataset as patients 16 years old with a clinical urine isolate taken in the community between January 2012 and June 2015. SARUIS records susceptibility data for up to 14 antibiotics for each isolate. EUCAST 14 susceptibility testing methodology was gradually introduced in the diagnostic and reference laboratories in Scotland during 2013. This may have resulted in small proportions of isolates that would have been reported as 'susceptible' under CSLI 15 methodology being reported as 'resistant' under the EUCAST methodology later in the study period. Testing and reporting practice varied between laboratories, meaning that not all isolates were tested against all antibiotics. From the standard testing panel across NHS Scotland, antibiotics were grouped into seven categories: 12 (i) agents used for the treatment of UTI in Scotland (ciprofloxacin/co-amoxiclav/nitrofurantoin/trimethoprim); (ii) extended-spectrum penicillins (ampicillin/amoxicillin); (iii) first-and second-generation cephalosporins (cefuroxime/ cefalexin); (iv) third-generation cephalosporins (cefotaxime/ceftazidime); (v) carbapenems (meropenem/ertapenem); (vi) aminoglycosides (gentamicin); and (vii) tetracyclines. Isolates were categorized as susceptible if susceptible to all antibiotics tested; resistant if resistant to one of the antibiotics tested; and MDR if resistant to at least one antibiotic in each of three or more categories. Patients with more than one isolate in the study period had the most resistant isolate selected or a random isolate selected if they were in the same resistance category.
Using SMR01, the number of hospital stays in the previous 12 months and a Charlson comorbidity score 16, 17 derived from ICD-10 18 discharge codes from the previous 5 years were calculated for each patient.
Using PIS, community antibiotic exposure in the previous 12 months was determined and quantified in DDDs. 19 Antibiotic exposure was classified as the number of different antibiotics and, separately, as the cumulative DDDs of all antibiotics, nitrofurantoin alone and trimethoprim alone, in the previous 6 months, and as the time interval between the urine isolate and the last prior antibiotic (in total, nitrofurantoin, trimethoprim) within 12 months.
The number of different drug classes, defined as paragraphs of the legacy British National Formulary (BNF), 20 a patient had dispensed in the previous 12 months was used as a comorbidity measure, in addition to the Charlson comorbidity score. Care home (long-term care facility in the community providing a supported care environment) residence was assigned if a patient had an admission to hospital from a care home (from SMR01) and/or was registered as a care home resident on a dispensed prescription (from PIS), in the previous 12 months.
Statistical analysis
Associations between gender, age group, comorbidity, previous hospitalization, care home residence, antibiotic exposure (measured as number of different antibiotics in previous 6 months) and urine isolate susceptibility (susceptible, resistant or MDR) were quantified using multinomial logistic regression, with susceptible as the reference category. Associations significant (P , 0.05) at univariate level were included in multivariate models.
Where the variable was an ordered factor, the P value for the linear trend was reported. Measurement of the association between both temporal and cumulative antimicrobial exposure was considered in separate models for exposure to each of (i) any antibiotic, (ii) nitrofurantoin, and (iii) trimethoprim. Again multinomial logistic regression was used adjusted for gender, age group, Charlson comorbidity score, drug classes prescribed in the previous 12 months, number of hospital stays in previous 12 months and care home residence in the previous 12 months. A sensitivity analysis was carried out (with number of different antibiotics as the antibiotic exposure variable), excluding patients with hospitalizations in the previous 12 months to negate the potential effect of any hospital prescribing on the associations observed as patient-level hospital prescribing data were not available. A separate subgroup analysis was conducted including isolates that had not been tested against at least one antibiotic from all seven categories.
Data manipulation was carried out in SPSS version 21 and analyses in R version 3.2.0.
Ethical approval
All study data were generated during routine care and had all patient identifiers removed prior to analysis. NSS Privacy Advisory Committee approval was granted and all analysis adhered to NSS Information Governance Policy and Procedures.
Results
Within the study period 40984 (62%) of 66194 urine isolates in SARUIS met the inclusion criteria. Of these, 11674 (28%) were susceptible, 18445 (45%) were resistant and 10892 (27%) were MDR, and E. coli accounted for 73% of all isolates (Table 1 ). More than half of all isolates were from people 65 years old, 79% were from female patients and 9% were from care home residents (Table 1) . One-third of patients had a Charlson comorbidity score of 1, but almost three-quarters had been prescribed drugs from 5 classes in the previous 12 months and 36% had a hospital stay in the previous 12 months (Table 1) . Just over one-third of patients had no antibiotic prescriptions in the prior 6 months and 5% had at least four different antibiotics (Table 1) . A total of 30% had 14 DDDs of antibiotic in the preceding 6 months and the mean time since last antibiotic prescription in the prior 12 months was 75 days (SD " 90) the median was 35 days (IQR " 104).
In univariate analyses, male gender, increasing age, comorbidity, hospitalization, care home residence, number of different drug classes and different antibiotics in the previous 6 months were all associated with increased risk of having resistant and MDR isolates ( Table 2 ). Associations remained in adjusted analysis, with higher Resistance risk factors in urines JAC The sensitivity analysis excluding patients with hospitalizations in the previous 12 months comprised 26020 patients (64% of the whole cohort). Age was no longer significantly associated with resistant isolates (P " 0.961), but remained strongly associated with MDR (P , 0.001), and the association between male gender and MDR was not significant (P " 0.08). Other associations, particularly higher numbers of different antibiotics, were similar to the main cohort analysis (Table S1 , available as Supplementary data at JAC Online). The subgroup analysis including only isolates not tested against at least one drug from all seven categories of antibiotics comprised 6386 patients (15.5% of the cohort). Most associations with resistance and MDR were similar to the main analysis, with the exception of gender not being significant and previous hospitalization not being associated with resistant isolates (Table S2) .
Cumulative exposure in the prior 6 months had dose-response effects on resistance and MDR, for total antibiotic, nitrofurantoin and trimethoprim exposures (Figures 1 and 2 ). For MDR, 29 DDDs versus no antibiotics in the previous 6 months had an OR of 6.54 (95% CI 5.88-7.27) for total antibiotic exposure, 8.56 (95% CI 6.56-11.18) for nitrofurantoin and 14.61 (95% CI 10.53-20.27) for trimethoprim ( Figure 2 ).
There were temporal associations between antibiotic exposure and resistance, particularly MDR ( Resistance risk factors in urines JAC 12 months previously (Table 3 ). Exposure to trimethoprim and to nitrofurantoin, compared with no antibiotics, in the previous 1 month had similar associations with MDR as for any antibiotic exposure, but effects persisted for longer and were still highly significant for exposure 10-12 months previously (nitrofurantoin OR 2.31, 95% CI 1.93-2.76 and trimethoprim OR 1.81, 95% CI 1.57-2.09) ( Table 3) .
Discussion
This study is, as far as we know, the first to use national patientlevel data linkage to characterize risk factors for AMR in community urine isolates and to examine MDR. We found that antibiotic exposure in the previous 6 months was strongly associated with MDR and the effect was stronger with greater cumulative exposure to any antibiotics, to nitrofurantoin and to trimethoprim. The risk of MDR remained elevated following last exposure to any antibiotics for 7-9 months and to nitrofurantoin and trimethoprim for 10-12 months. We also found increasing age, comorbidity (Charlson comorbidity score and drug classes), hospitalization in the previous 12 months and care home residence to be significantly associated with resistance and MDR after adjustment of other factors.
Previous studies of resistance risk factors in community urine isolates have focused on exposure to a single or 'any' undefined antibiotic and associations of resistance to one or two antibiotics, without examining MDR. Such studies were small scale (n " 398-8833), in single regions rather than at national level and were over 10 years old. [21] [22] [23] Our study established that exposure to even one type of antibiotic within the previous 6 months was associated with resistance (OR 1.19, 95% CI 1.12-1.26) after adjustment for other factors. Steinke et al. 21 reported that isolates with trimethoprim resistance were strongly independently associated with trimethoprim exposure (OR 4.35, 95% CI 3.03-5.73) and to any other antibiotics (OR 1.32, 95% CI 1.10-1.60) in the 6 months prior to the isolate. Donnan et al. 22 reported that trimethoprim resistance was independently associated with 1 prescription for trimethoprim (OR 1.22, 95% CI 1.16-1.28) and to 1 prescription for other antibiotics (OR 1.18, 95% CI 1.06-1.32) in the 6 months prior to the isolate. Dromigny et al. 23 reported that prior exposure to any antibiotics was an independent risk factor for trimethoprim/sulfamethoxazole resistance (OR 2.4, 95% CI 1.4-4.1). Our study demonstrated a relationship between prior antibiotic use and resistance to single antibiotics, but, more importantly, to MDR. We have established that use 25 in a study in 12 UK general practices reported OR 3.14 (95% CI 0.63-15.6) for resistance to amoxicillin and/or trimethoprim associated with 4 courses of antibiotics in 12 months in patients with E. coli urine isolates. Our study established that increasing cumulative exposure to antibiotics was associated with resistance. Moreover it demonstrates a dose-response relationship between cumulative total antibiotic, nitrofurantoin or trimethoprim exposure and MDR that has not been reported previously.
The period of increased risk of resistance following antibiotic exposure is important. A meta-analysis (14348 participants) by Costelloe et al. 26 demonstrated a pooled OR of 1.33 (95% CI 1.15-1.53) for associations with resistance in those exposed to trimethoprim, amoxicillin or any antibiotic in the previous 12 months, but only included resistance to single antibiotics. In a more recent study, Duffy et al. 27 found that associations with trimethoprim use and resistance were not significant beyond 84 days since last exposure in community urinary isolates from children (n " 1373). Importantly, our study extends this evidence to the impact of antibiotic use on MDR. We found the effect on MDR of any antibiotic exposure was still evident at 7-9 months (OR 1.27, 95% CI 1.12-1.45). For individuals whose most recent exposure to trimethoprim was up to 10-12 months prior to the positive isolate, we found the effect on MDR was still significant at 10-12 months post-exposure (OR 1.80, 95% CI 1.66-1.95) and the effect was even greater following exposure to nitrofurantoin (OR 2.31, 95% CI 1.93-2.76).
Previous reports of an association between nitrofurantoin resistance in E. coli isolates in Finland were at population level rather than individual level. 28 Our study is, as far as we know, the first to establish patient-level associations between nitrofurantoin exposure and resistance and MDR. Here, we report that exposure to 29 DDDs of nitrofurantoin in the previous 6 months increased the OR of MDR to 8.56 (95% CI 6.56-11.18).
We identified risk factors other than antibiotic exposure to be associated with increased odds of MDR. The adjusted effect of care home residence we report (OR 3.36, 95% CI 2.95-3.83) was similar to the adjusted OR reported by Faine et al. 29 (4.17, 95% CI 1.13-15.3) for MDR in 360 patients with UTI in an emergency department setting. We found that as the number of hospitalizations in the previous 12 months increased, so too did the odds of MDR. Our finding is different to a small study (n " 828) by Steinke et al., 30 in a single region in Scotland, which found that hospitalization in the previous 6 months was not independently associated with trimethoprim resistance. Male gender and increasing age have been associated with resistance in other studies and our findings are similar. 21, 22, 29, 31 Of the risk factors assessed in this study, antibiotic exposure is the most important as it had the strongest association with resistance and is modifiable through antibiotic stewardship interventions. There is evidence that in some uncomplicated UTIs in adult females, symptomatic relief with ibuprofen is non-inferior to antibiotics. 32 Our results should support efforts to reduce unnecessary use of any antibiotics to reduce selection pressure for resistance and especially MDR. The recommendation of the European Association of Urology 33 to review and consider discontinuation of antibiotic prophylaxis of UTI is important given the association between cumulative use of antibiotics and MDR demonstrated in our study.
A recent review highlighted the importance of linkage of prescription and outcome data to improve understanding of the risks of and outcomes from AMR in UTI and called for the outputs from such data linkage studies to inform clinical decision making, prescribing practice and guideline development. 34 Our findings demonstrate that the risk of resistance to antibiotics, especially those commonly used for treatment of UTI, is influenced by factors such as age, gender, comorbidity, previous hospitalization, care home residence and antibiotic exposure.
The strengths of our study include that it was conducted at national level using data collected as part of routine clinical practice. As the data source for urine isolates was a national database these data should be representative of all urine isolates collected in the community. The inclusion of MDR as an outcome was a further strength as previous studies have focused on resistance to single antibiotics or a small subgroup of antibiotics, which takes no account of MDR. [21] [22] [23] We also examined cumulative and temporal associations between resistance and exposure to all antibiotics, nitrofurantoin and trimethoprim. The sensitivity analysis excluding patients with hospitalizations in the previous 12 months removes any impact on resistance of antibiotic exposure in hospital, which presently is not captured at the individual patient level across all of Scotland, or of recent transmission in hospital.
The work has several limitations that may limit our findings' generalizability to all UTIs. Samples collected in the community and submitted for culture and susceptibility to microbiology departments will be biased towards resistance as samples may only be submitted in complicated cases or in cases where patients have failed on initial empirical treatment. This bias, while overestimating the true prevalence of resistance in urine isolates, should not impact on the association between resistance and other variables. Furthermore, the susceptibility data included in the analysis are dependent on testing carried out in, and national reporting from, individual diagnostic laboratories so we did not have results for all isolates tested against all antibiotics. However, subgroup analysis on those isolates (n " 6386; 16% of total isolates) not tested against all seven categories of antibiotics yielded similar results.
This national-level data linkage study has for the first time, as far as we know, quantified the risk of MDR associated in community urine isolates. We demonstrated a dose-response relationship with MDR increasing with increased cumulative antibiotic exposure. The risk of MDR was highest within 1 month of antibiotic exposure, but an effect for nitrofurantoin and trimethoprim remained for up to 12 months after the last exposure. These data will be used to design and test a clinical decision support tool which could enable clinicians to identify patients, at the point of writing the prescription, who are at high risk of resistance.
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